within Pharmacolibrary.Drugs.N_NervousSystem.N01B_AnestheticsLocal.N01BX04_Capsaicin;

model Capsaicin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.4999999999999998e-05,
    adminDuration = 600,
    adminMass = 8 / 1000000,
    adminCount = 1,
    Vd = 0.003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Capsaicin</td></tr><tr><td>ATC code:</td><td>N01BX04</td></tr><td>route:</td><td>topical</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>90</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Capsaicin is a naturally occurring alkaloid found in chili peppers and is the active component responsible for their pungency. It is used topically for the relief of neuropathic and musculoskeletal pain, such as in postherpetic neuralgia and osteoarthritis. While capsaicin is effective for pain management, it is not systemically approved as an analgesic for other indications and is primarily used in topical formulations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic properties of capsaicin for topical administration in adults, as published data on systemic pharmacokinetics are very limited due to poor absorption and rapid metabolism. Systemic exposure following topical or dietary administration is very low.</p><h4>References</h4><ol><li><p>Babbar, S, et al., &amp; Bley, K (2009). Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. <i>Therapeutic drug monitoring</i> 31(4) 502–510. DOI:<a href=\"https://doi.org/10.1097/FTD.0b013e3181a8b200\">10.1097/FTD.0b013e3181a8b200</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19494795/\">https://pubmed.ncbi.nlm.nih.gov/19494795</a></p></li><li><p>Kalliomäki, J, et al., &amp; Simpson, DM (2013). Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. <i>Scandinavian journal of pain</i> 4(2) 77–83. DOI:<a href=\"https://doi.org/10.1016/j.sjpain.2012.10.003\">10.1016/j.sjpain.2012.10.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29913894/\">https://pubmed.ncbi.nlm.nih.gov/29913894</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N01BX04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Capsaicin;
